This #LaborDay, we honor the dedication and hard work of all professionals, particularly our healthcare professionals, researchers, and advocates striving to improve the lives of others. Your tireless efforts inspire us every day as we work towards fighting rare diseases. Together, we can create a healthier future for families everywhere. Thank you for your unwavering commitment and passion. Happy Labor Day!
Rallybio
Biotechnology Research
New Haven, Connecticut 4,286 followers
Unimagined therapies. Undreamed outcomes.
About us
We are making science’s hardest obstacles our highest priority. Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Rallybio is headquartered in New Haven, Connecticut. Our success depends on rallying the best people, partners, and science. It hinges on fearlessly creating paths forward as we strive to develop and deliver the truly transformational. Read our Community Guidelines here: https://bit.ly/RLYBCGs
- Website
-
https://rallybio.com/
External link for Rallybio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- New Haven, Connecticut
- Type
- Public Company
- Founded
- 2018
- Specialties
- Rare Disease
Locations
-
Primary
234 Church Street
Suite 1020
New Haven, Connecticut 06510, US
Employees at Rallybio
Updates
-
This morning Rallybio announced our Q2 2024 financial results. Read our press release: https://lnkd.in/eBJi3yq7 $RLYB #biotech #earnings
-
Women face distinct challenges with chronic conditions that are often misunderstood and under-researched. A new report from the National Academies of Sciences, Engineering, and Medicine calls on the National Institutes of Health and other federal research agencies to enhance their research efforts to better understand chronic conditions in women. Read more here: https://lnkd.in/gjMnaNCG #WomensHealth #ResearchMatters
Significant Lack of Data and Research on Chronic Conditions Affecting Women Is Hindering Diagnosis, Treatment, and Prevention; Report Calls for Enhanced NIH Research Effort
nationalacademies.org
-
Rallybio reposted this
Insights about leadership in biopharma from the conversation between Stephen Uden, co-founder and CEO Rallybio, and John Simboli, Principal Wyant Simboli
New BioBoss podcast https://lnkd.in/eCCWehij featuring Stephen Uden, co-founder and CEO of Rallybio. Hear Steve speak with BioBoss host and Wyant Simboli principal John Simboli about leadership in biopharma and how Rallybio is working to profoundly change the odds for patients living with rare diseases. #BioBoss,#leadership,#innovation,#entrepreneurship,#biopharma,#biotech,#technology, #lifescience, #FNAIT, #myastheniagravis, #MG, #raredisease, #maternalhealth, #fetalhealth, #womenshealth, #newbornscreening
-
-
Thrilled to announce the publication of our latest paper, "Integrated Applied Clinical Pharmacology in the Advancement of Rare and Ultra-Rare Disease Therapeutics." This work highlights the critical role of clinical pharmacology in developing effective treatments for rare and ultra-rare diseases, showcasing two case studies: C5-targeted therapeutics for generalized myasthenia gravis and asfotase alpha for hypophosphatasia. Read more about our integrative approach and findings from our Chief Medical Officer Steve Ryder here: https://lnkd.in/eXxuux9A
Integrated Applied Clinical Pharmacology in the Advancement of Rare and Ultra‐Rare Disease Therapeutics
ascpt.onlinelibrary.wiley.com
-
Happy #IndependenceDay from Rallybio! Wishing you a safe 4th of July as we celebrate the spirit of freedom and independence. #July4
-
-
Did you know that June is Myasthenia gravis (MG) awareness month? MG is a chronic autoimmune disease that causes weakness in the body's voluntary muscles. Our team at Rallybio is committed to raising awareness of the challenges and opportunities faced by those who battle rare diseases like myasthenia gravis every day. #myastheniagravis #MG
-
Happy Pride from Rallybio! June is a time to celebrate the progress that has been made and look forward to the work that remains to ensure queer people feel valued and seen in their workplaces and beyond. #Pride #HappyPride
-
-
This #Juneteenth, we at Rallybio invite our colleagues, partners, and stakeholders to join us in reaffirming our commitment to creating a better future for all. Today, we reflect on the impact racial injustice and inequality have had on our history and how we can create lasting change. The Rallybio team is committed to advancing #healthequity and honoring the legacy of those who have fought for freedom, justice, and equality.
Similar pages
Browse jobs
Stock
RLYB
NASDAQ
20 minutes delay
$1.10
-0.05 (-4.348%)
- Open
- 1.15
- Low
- 1.1
- High
- 1.19
Data from Refinitiv
See more info on